Type 1 diabetes – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Type 1 diabetes has traditionally been diagnosed based on clinical catabolic symptoms suggestive of insulin deficiency: polyuria, polydipsia, weight loss, and marked hyperglycemia that is nonresponsive to oral agents. It is categorized as an autoimmune disease with progressive b-cell destruction, resulting in a physiological dependence on exogenous insulin. Recent studies have broadened our understanding of the disease but have made diagnosis more complex. Type 1 diabetes care must be an iterative process, adapted as the needs of the individual evolve. In children and adults, clinical assessments for type 1 diabetes should incorporate age-appropriate and complication-focused evaluations based on the possibility that an abnormality will be present. A young adult with common cardiovascular disease (CVD) risk and no complications may need more assessment of lifestyle adjustment than an older adult with a long time of the disease who may need more vascular and neurological issues evaluation.

The prevalence rate of Type 1 diabetes varies from 0.06% to 0.1% among all the population in the USA

The competitive landscape of Type 1 diabetes includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Type 1 diabetes across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Type 1 diabetes Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Type 1 diabetes – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Teplizumab       MacoGenics      Phase 3

2          IMT-002            Immunomolecular Therapeutics, Inc.      Phase 1

3          ORMD-0801     Oramed, Ltd.     Phase 2

4          Dapagliflozin     AstraZeneca     Phase 3

5          Albiglutide         GlaxoSmithKline            Phase 2

6          Humalog           Halozyme Therapeutics Phase 2

7          Sotagliflozin      Lexicon Pharmaceuticals           Phase 2

8          ADO09 Adocia  Phase 2

9          Alpha-1 Antitrypsin        Kamada, Ltd.    Phase 2

10        IMCY-0098       Imcyse SA        Phase 2

Continued
 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033